NexGel, Inc Warrant - NXGLW STOCK NEWS

NEXGEL (NASDAQ: NXGL) has acquired Silly George, an international beauty brand specializing in eye and eyelash products, for $400,000 in cash, $200,000 in NEXGEL common stock, and a 4-year net profit earn out. Silly George, with a revenue run rate of approximately $2 million, offers a range of products including non-toxic eyelash extensions and lash serums, predominantly sold direct-to-consumer and on Amazon in the U.S., U.K., Australia, and the Netherlands. The acquisition is expected to add $2 million in annual revenue and provides operational synergies through marketing optimization and expense overlap. Silly George's strong social media presence and customer database will also offer cross-selling opportunities for NEXGEL's portfolio. CEO Adam Levy highlighted the acquisition as a strategic move towards profitability, leveraging synergies and expanding their product portfolio in the health and beauty sector.

NEXGEL (NASDAQ: NXGL) announced its financial results for Q1 2024, reporting a 104% YoY revenue increase to $1.27 million, driven by 58% growth in contract manufacturing and 178% in consumer branded products. The gross profit for Q1 2024 was $277,000, up from a loss of $57,000 in Q1 2023. However, the company reported a net loss of $905,000, up from $807,000 in the same period last year. NEXGEL is investing in significant growth opportunities, including expanding its Texas facility and launching products in Europe. The company ended the quarter with a cash balance of $2.4 million.

NEXGEL, Inc. will report its first quarter 2024 financial results on May 13th, followed by a conference call at 4:30 P.M. ET. The company is a leading provider of medical and over-the-counter products, including hydrogels for healthcare and consumer applications.

NEXGEL, Inc. will be presenting at the Aegis Capital Virtual Conference on May 9, 2024. The company specializes in medical and OTC products, such as hydrogels, for healthcare and consumer use. The CEO, Adam Levy, will be the speaker at the conference.

NEXGEL, Inc. to present at the Planet MicroCap Showcase: VEGAS 2024 on May 1 & 2, 2024. The CEO, Adam Levy, will be presenting at the event. NEXGEL is a leading provider of medical and OTC products, including hydrogels for healthcare and consumer applications.

NEXGEL, Inc. reported a record year in 2023 with nearly 100% revenue growth driven by branded products and contract manufacturing. The company expanded its operational infrastructure, secured key partnerships, and made strategic investments for future growth. Financially, revenue for 2023 was $4.1 million, a 99.7% increase from 2022, with gross profit margin improving to 15.2%. Despite revenue growth, cost of revenues and selling, general, and administrative expenses also increased. NEXGEL ended 2023 with a net loss of $3.2 million but had $2.7 million in cash. The company expects first quarter revenue of $1.25 million, excluding a non-refundable deposit from AbbVie. Overall, NEXGEL is positioning itself for significant growth in 2024.

NEXGEL, Inc. reschedules its financial results conference call for the fourth quarter and full year 2023 to Monday, April 1st at 8:30 a.m. ET due to the Good Friday holiday closure. CEO Adam Levy aims to enhance visibility and convenience for shareholders.

NEXGEL, Inc. will report its financial results for Q4 and full year 2023 on March 28, 2024. The Company specializes in medical and OTC products, including hydrogels. A conference call will follow the release of financial results at 4:30 P.M. ET on the same day.

NEXGEL, Inc. announced that CEO Adam Levy will present at the iAccess Alpha Best Ideas Spring Virtual Conference on March 12th, 2024. NEXGEL is a prominent provider of medical and OTC products, specializing in hydrogels for healthcare and consumer use.